All PlansBilling CodesHigh impact
New Claims Editing Rules To Be Implemented in December 2026
BCBS Texas·TX · Ophthalmology, Endocrinology·Reimbursement
Effective date
Dec 1, 2026
We identified it
Aug 22, 2026
Summary
Blue Cross Blue Shield of Texas is implementing new claims editing rules effective December 1, 2026, that will enforce specific unit limits on five specialty injectable drugs (Denosumab, Aflibercept, Ranibizumab, Pasireotide, and Ranibizumab-eqrn) and require proper application of drug wastage modifiers on single-use vial claims. Claims that fail these edits will receive ineligible reason codes beginning with 'G.' Billing teams must update systems and provider education to comply with these new frequency and unit limitations.
Action Required
By November 15, 2026: Billing team must update Lyric software and claims editing system to enforce the following unit limits: J0897 (Denosumab) maximum 60 units every 6 months for osteoporosis diagnosis; J0178 (Aflibercept) maximum 4 units every 4 weeks; J2778 (Ranibizumab) maximum 5 units every 4 weeks; J2502 (Pasireotide) maximum 60 units every 4 weeks for acromegaly diagnosis; Q5128 (Ranibizumab-eqrn) maximum 10 units every 4 weeks for wet AMD, RVO, or myopic CNV diagnoses. Additionally, configure system to flag single-use vial/package drug codes missing JW or JZ drug wastage modifiers. Notify all providers and clinical staff of these new limits via training session or written communication. Update billing templates and charge capture forms to include these code-specific limits. Configure system to generate 'G' prefixed denial codes for failed edits. Establish audit process to review denied claims post-implementation. Failure to comply will result in claim denials and revenue loss for affected specialty drug administrations.